Your browser doesn't support javascript.
loading
Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies.
Burger, Jan A; Cramer, Paula; Barr, Paul M; Dilhuydy, Marie-Sarah; Mato, Anthony; Byrd, John C; Chang, Stephen; Graef, Thorsten; Lin, Tony; Tedeschi, Alessandra.
Afiliação
  • Burger JA; University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cramer P; German CLL Study Group, University of Cologne, Cologne, Germany.
  • Barr PM; University of Rochester Cancer Center, Rochester, NY, USA.
  • Dilhuydy MS; Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
  • Mato A; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
  • Byrd JC; The Ohio State University, Columbus, OH, USA.
  • Chang S; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Graef T; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Lin T; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Tedeschi A; Azienda Ospedaliera Niguarda Cà Granda, Milan, Italy.
Br J Haematol ; 186(1): 175-180, 2019 07.
Article em En | MEDLINE | ID: mdl-30739324
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Leucemia Linfocítica Crônica de Células B Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article